We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
IMC Retains Expression Analysis for Affymetrix GeneChip® Processing Services
News

IMC Retains Expression Analysis for Affymetrix GeneChip® Processing Services

IMC Retains Expression Analysis for Affymetrix GeneChip® Processing Services
News

IMC Retains Expression Analysis for Affymetrix GeneChip® Processing Services

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "IMC Retains Expression Analysis for Affymetrix GeneChip® Processing Services "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Expression Analysis, Inc. has entered into an agreement with IMC to provide isolation of genomic samples and Affymetrix microarray processing for samples from a clinical trial IMC is conducting on an award from the National Institute on Drug Abuse

IMC received a grant last year from the National Institute on Drug Abuse to conduct a clinical trial utilizing their software, TeraGenomics, a high performance data warehousing solution for managing, analyzing and sharing Affymetrix GeneChip® microarray data to analyze the effectiveness of a compound used to treat addiction to methamphetamine.

After researching the market for a vendor to process the microarrays involved in the study, as well as some ancillary services, IMC decided on Expression Analysis.

"We felt Expression Analysis provided the expertise, capabilities and flexibility we required in a microarray processing partner because of the way we knew this project would evolve and change as it progressed," said Gregg Wright, Sr. VP Business Development and Solutions at IMC.

"Besides being price competitive, Expression Analysis demonstrated a willingness to work with us to solve process problems as they became apparent."

Expression Analysis will isolate genomic samples and analyze those on both gene expression and genotyping microarrays for IMC.

"We are very pleased that IMC has selected us to provide these services for their project," said Steve McPhail, President and CEO of Expression Analysis.

He continued, "We have built our business model around providing microarray services in a regulatory compliant environment, and focusing on communications and flexibility with clients in meeting their needs."

"The projects our clients bring us continue to validate our plan of supporting the value of microarray data generation in clinical trials."

Advertisement